Acorda’s awful, no good, just plain bad week gets worse as FDA hands execs another delay on Inbrija — battered shares tumble again
Acorda’s snafu-plagued attempt to get a fast FDA marketing decision on a critically important new drug has just run into a fresh setback — and it’s painful to watch.
Two days after the biotech’s shares $ACOR cratered on the loss of an appeal aimed at protecting its patents on Ampyra — its only real asset on the market — the biotech is back with news that the FDA wants more time to consider new info it asked for on CMC related to Inbrija (levodopa inhalation powder), adding a three-month delay to the process and extending the PDUFA to January 5 of next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
